Home › Research › Treatments
Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results
ADAPT Research Group, Meinert CL, McCaffrey LD, Breitner JC.. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2009-03-01
Topic: Amyloid, tau and blood-test diagnosis
Background The Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) was designed to address whether non-steroidal anti-inflammatory drugs (NSAIDs) can prevent or delay the onset of Alzheimer's disease (AD). Methods ADAPT was a randomized, double-placebo-controlled, multicenter chemoprevention trial conducted at six U.S. dementia research clinics. At entry, participants were required to test "normal" on a battery of cognitive tests and to be age 70+ with a family history of Alzheimer-like dementia. Persons were randomly assigned to 200 mg b.i.d. celecoxib (Celebrex, Pfizer), 220 mg b.i.d. naproxen sodium (Aleve, Bayer), or placebo. The primary outcome measure was AD. Secondary outcome measures were cognitive decline and measures related to safety of the treatments when used long term. ADAPT was designed to detect a 30% reduction in AD incidence with 80% power. The estimated sample size requirement was 2,625. Results Enrollment began in March 2001 and ended in December 2004 when treatments were suspended because of concerns regarding cardiovascular safety of the treatments. Followup ranged from 1 to 46 months. The achieved enrollment was 2,528. Recruitment was achieved primarily via mailings to people aged 70+ living in the catchment areas of the six field sites.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
ADAPT Research Group, Meinert, C. L., McCaffrey, L. D., & Breitner, J. C. (2009). Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1016/j.jalz.2008.09.004
Vancouver
ADAPT Research Group, Meinert CL, McCaffrey LD, Breitner JC. Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2009. doi:10.1016/j.jalz.2008.09.004. PMID: 19328435.
BibTeX
@article{study2009-19328435,
author = {{ADAPT Research Group} and Meinert, C. L. and McCaffrey, L. D. and Breitner, J. C.},
title = {{Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results}},
journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
year = {2009},
doi = {10.1016/j.jalz.2008.09.004},
pmid = {19328435},
url = {https://doi.org/10.1016/j.jalz.2008.09.004}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results Enrollment began in March 2001 and ended in December 2004 when treatments were suspended because of concerns regarding cardiovascular safety of the treatments.
Why it matters
This paper describes the design of a prevention trial testing whether the anti-inflammatory drugs celecoxib or naproxen could prevent Alzheimer's disease in people aged 70 and older with a family history of dementia. The trial enrolled 2,528 participants but treatments were suspended early because of concerns about cardiovascular safety, so it did not provide answers about prevention.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthHigh
How this study scored 63/100
Published in a leading specialty journal, and it is a randomised controlled trial. Scored zero for sample size and effect reported because the record does not state it. We have no data on senior author's track record and institution's track record, so those were left out: it earned 59 of the 93 points we could judge it on, which is 63 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomised controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2009 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (pubmed indexes it as a clinical or observational study) |
| Randomised / blinded | 2 / 2 | Randomised and blinded or placebo-controlled (as stated in the record) |
| Times cited | 4 / 7 | Cited 99 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 5.2 citations a year over 19 year(s) since 2009 |
| Impact for its field and year | 3 / 6 | Cited 7.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 5 other studies in this library |
| Still being cited | 1 / 4 | Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author ADAPT Research Group holds only 2 work(s), too few to judge a track record — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | 2 / 3 | PubMed indexes it as a multicentre study |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 19328435) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 59 / 93 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 59 of the 93 points we could judge it on is 63 out of 100. |
| Total | 63 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
5 studies in the alzhub library list this one in their references.
Related studies in Treatments
Also in Treatments
166 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.